Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
I am delighted to offer this quarterly update on our expectations for the fourth quarter and to unveil our 2024 guidance.
- I am delighted to offer this quarterly update on our expectations for the fourth quarter and to unveil our 2024 guidance.
- Guidance for 2023 and 2024:
The Company is updating guidance for the remainder of 2023 and establishing guidance for the full year 2024 that reflects the growth potential of the product portfolio and the output of our continual operational improvements. - Full-year 2023 net product sales guidance for the oncology care franchise is being increased to a range of $104 million to $106 million from a prior range of $99 million to $103 million.
- EBITDA (excluding stock compensation) expected in the range of ($10 million) to ($6 million) in the fourth quarter of 2023.